Diffuse Large B Cell Lymphoma (dlbcl) - Pharma

Relevant Publications

Analysis of CCND3 mutations in diffuse large B-cell lymphoma.

Issue Release: 2024

Cholesterol efflux from C1QB-expressing macrophages is associated with resistance to chimeric antigen receptor T cell therapy in primary refractory diffuse large B cell lymphoma.

Issue Release: 2024

Quality of life assessment in diffuse large B-cell lymphoma (DLBCL) in REFLECT: a prospective, non-interventional, multicenter, German study, assessing Sandoz rituximab in combination with CHOP.

Issue Release: 2024

Cystatin SN (CST1) Is a Poor Independent Prognostic Biomarker for Gastrointestinal Diffuse Large B-Cell Lymphoma.

Issue Release: 2024

Tolerance of radiotherapy with concomitant glofitamab in diffuse large B cell lymphoma: a case report.

Issue Release: 2024

Coexistence of large cell transformed mycosis fungoides and diffuse large B-cell lymphoma in one patient.

Issue Release: 2024

FDG-PET in HIV-Positive Patient with Extranodal Diffuse Large B-Cell Lymphoma.

Issue Release: 2024

Central nervous system relapse after combination therapy including polatuzumab vedotin in patients with diffuse large B-cell lymphoma.

Issue Release: 2024

Transcriptomic classification of diffuse large B-cell lymphoma identifies a high-risk activated B-cell-like subpopulation with targetable MYC dysregulation.

Issue Release: 2024

Clinical characteristics and outcome of early-stage diffuse large B cell lymphoma of female genital track: A retrospective study of the Hellenic cooperative lymphoma group.

Issue Release: 2024

Epidermodysplasia Verruciformis and Vδ2 γδ T-cell Expansion in STK4 Deficiency.

Issue Release: 2024

Arterial effects of anthracycline: structural and inflammatory assessments in non-human primates and lymphoma patients using F-FDG positron emission tomography.

Issue Release: 2024

Is There an Immunohistochemical PD-L1 Cut-Off Point That Serves as a Prognostic Indicator for Large B-Cell Lymphomas?

Issue Release: 2024

Identifying Targetable Vulnerabilities to Circumvent or Overcome Venetoclax Resistance in Diffuse Large B-Cell Lymphoma.

Issue Release: 2024

Cardiac Tamponade: An Initial Manifestation of Diffuse Large B Cell Lymphoma.

Issue Release: 2024

Ibrutinib and R-GemOx in patients with relapsed or refractory diffuse large B-cell lymphoma of non-GCB type: Phase II clinical trial of the Spanish GELTAMO group.

Issue Release: 2024

Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma.

Issue Release: 2024

PET-based radiomic feature based on the cross-combination method for predicting the mid-term efficacy and prognosis in high-risk diffuse large B-cell lymphoma patients.

Issue Release: 2024

Cardiovascular mortality among patients with diffuse large B-cell lymphoma: a population-based study.

Issue Release: 2024

Network Pharmacology, Molecular Docking, and Experimental Validation of the Mechanism of Jiedu Xiaoliu Formula against Diffuse Large B-Cell Lymphoma.

Issue Release: 2024

Who are Pharmacists?

How Can Pharmacists Contribute to Transitional Care?

What is an Abbreviated New Drug Application (ANDA)?

What Strategies do Brand-Name Companies Use to Delay Generic Entry?

What is the Future of ADE Management?

Why is the Management of Chronic Conditions Important?

What is Medication Adherence?

How Can Technology Aid in Patient Education?

What Role Do Pharmacists Play in Patient Education?

How Do Pharmacists Contribute to Patient Care?

Diffuse Large B Cell Lymphoma (dlbcl) - Pharma

Relevant Publications

Partnered Content Networks

Relevant Topics